Trial Profile
An Open-Label, Multicenter Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution 0.002% in Latanoprost Low/Non-Responder Subjects Diagnosed With Primary Open-Angle Glaucoma or Ocular Hypertension - Spectrum 5 Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Jan 2024
Price :
$35
*
At a glance
- Drugs Omidenepag isopropyl (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Registrational; Therapeutic Use
- Acronyms Spectrum 5
- Sponsors Santen Inc
- 01 Dec 2023 Primary endpoint has been met. (Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) at Month 3.)
- 01 Dec 2023 Results evaluating the intraocular pressure (IOP)-lowering efficacy and safety of OMDI in latanoprost low/nonresponders with POAG or OHT, published in the Journal of Glaucoma
- 08 Aug 2023 Status changed from recruiting to completed.